购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Others
    (2)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 5日内发货
    (8)
  • 35日内发货
    (1)
筛选
搜索结果
TargetMol产品目录中 "

ert 1

"的结果
  • 抑制剂&激动剂
    2
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    3
    TargetMol | Recombinant_Protein
  • 天然产物
    2
    TargetMol | Natural_Products
  • 检测抗体
    6
    TargetMol | Antibody_Products
  • Pseudoginsenoside RT1
    拟人参皂苷 RT1, 假人参皂苷RT1
    T4S151898474-74-9
    Pseudoginsenoside RT1 是分离自 Randia siamensis 中,具有鱼毒素作用。它可导致血压下降、心率加快和子宫自发收缩力增加。
    • ¥ 167
    In stock
    规格
    数量
  • Lyso-Globotriaosylceramide (d18:1)
    Lyso-Globotriaosylceramide (d18:1)
    T37291126550-86-5
    Lyso-globotriaosylceramide is a form of globotriaosylceramide that is lacking the fatty acyl group. It binds to Shiga toxin 1 (Stx1) in the presence of cholesterol and phosphatidylcholine but does not bind Stx2. It also reduces viability and aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate when used at concentrations of 50 and 1 μM, respectively. Lyso-globotriaosylceramide accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. It also accumulates in the urine, kidney, and plasma of patients with Fabry disease. Lyso-globotriaosylceramide levels decrease in response to administration of the α-galactosidase inhibitor 1-deoxygalactonojirimycin in a transgenic mouse model of Fabry disease. Decreases in plasma and urine concentrations of lyso-globotriaosylceramide have been used as a biomarker for efficacy of enzyme replacement therapy (ERT) and other therapies in the treatment of Fabry disease.
    • 待估
    35日内发货
    规格
    数量